Piper Sandler Initiates Coverage On BridgeBio Pharma with Overweight Rating, Announces Price Target of $46
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler has initiated coverage on BridgeBio Pharma with an Overweight rating and set a price target of $46.
September 04, 2024 | 2:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler has initiated coverage on BridgeBio Pharma with an Overweight rating and a price target of $46, indicating a positive outlook on the stock.
The initiation of coverage with an Overweight rating and a specific price target of $46 by Piper Sandler suggests a positive sentiment towards BridgeBio Pharma. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100